Abstract: The present disclosure relates to a compound of Formula I, or a geometric isomer, enantiomer, diastereomer, racemate, atropisomer, pharmaceutically acceptable salt, prodrug or solvate thereof. The present disclosure further relates to a composition comprising the compound of Formula (I). The compound and the composition described herein can be used to inhibit NADPH oxidase activity.

Abstract: The compounds represented by Formula (I), which are peripheral alkyl and alkenyl chains extended benzene derivatives, are useful as dual autotaxin (ATX)/histone deacetylase (HD AC) inhibitors. These compounds may be included in a pharmaceutical composition along with a pharmaceutically acceptable carrier, and be used in a therapeutically effective amount for prophylaxis or treatment of various diseases and disorders.

Abstract: A novel structure of an opioid antagonist is provided. One of the exemplary compounds of the present disclosure has the structure of Formula (II). The present disclosure overcomes the discomfort of conventional opioid antagonist due to rapid absorption and improves the patient compliance thereof.

Abstract: The present disclosure relates to a compound of Formula I, or a geometric isomer, enantiomer, diastereomer, racemate, atropisomer, pharmaceutically acceptable salt, prodrug or solvate thereof. The present disclosure further relates to a composition comprising the compound of Formula (I). The compound and the composition described herein can be used to inhibit NADPH oxidase activity.

Abstract: A novel structure of an opioid antagonist is provided. One of the exemplary compounds of the present disclosure has the structure of Formula (II). The present disclosure overcomes the discomfort of conventional opioid antagonist due to rapid absorption and improves the patient compliance thereof.

Abstract: The present disclosure provides a benzene fused heterocyclic derivative of Formula (I): is a single or double bond; n is an integer of 0 or 1; A is —CH2—, —CH(OH)—, or —C(O)—; G is C or N; X is —CH2—, O, or —C(O)—; Y is alkyl, aryl, or heterocyclic alkyl optionally substituted with at least one substituent independently selected from a group consisting of: H, halogen, alkyl, alkyl substituted with at least one halogen, aryl, aryl substituted with at least one halogen, —NRy1Ry2, —ORy1, —Ry1C(O)Ry3, —C(O)Ry1, —C(O)ORy2, —C(O)ORy2Ry3, —NRy1C(O)Ry2, —NRy1C(O)NRy2Ry3, —NRy1C(O)ORy2Ry3, —NRy1C(O)Ry2ORy3, C(O)NRy1(Ry2Ry3), —C(O)NRy1(Ry2ORy1), —ORy2Ry3, and —ORy2ORy3, wherein each of Ry1 and Ry2 is independently selected from a group consisting of H, oxygen, alkyl, and aryl, and Ry3 is aryl optionally substituted with at least one halogen; Z is —NRz1Rz2, —NRz1Rz3, —ORz1, —ORz1Rz3, —C(O)Rz1Rz3, —C(O)ORz1Rz3, —NRz1C(O)Rz2Rz3, —NRz1C(O)ORz2Rz3, —C(O)NRz1Rz3, or ORz2ORz3, wherein each of Rz1 and Rz2 is independently sel

Abstract: Novel antagonists of toll-like receptor 4 (TLR-4) are provided. More specifically, the novel antagonists of TLR-4 are derived from morphinan. Further, use of said morphinan derivatives in the treatment of diseases and/or disorders mediated by TLR-4, such as autoimmune diseases, inflammation disease and infectious diseases, is provided. Pharmaceutical compositions including said morphinan derivatives are also provided.

Abstract: The present disclosure provides a sustained release formulation of opioid receptor antagonists comprising a sustained release granule comprising at least one of the opioid receptor antagonist, at least one of pharmaceutical acceptable carrier, and a pH-dependent polymer, wherein the sustained release granule is coated with the pH-dependent polymer, and the opioid receptor antagonist is selected from the group consisting of Nalmefene, Naltrexone, or a salt thereof.

Abstract: The present invention related to novel sulfonamides or amides as TLR-4 antagonists, and pharmaceutical formulations containing the same and the methods of use thereof. Uses of the present novel sulfonamides or amides include, but are not limited to, the prophylaxis and/or treatment of autoimmune, inflammation, or infection related disorders.

Abstract: The present disclosure provides a benzene fused heterocyclic derivative of Formula (I): is a single or double bond; n is an integer of 0 or 1; A is —CH2—, —CH(OH)—, or —C(O)—; G is C or N; X is —CH2—, O, or —C(O)—; Y is alkyl, aryl, or heterocyclic alkyl optionally substituted with at least one substituent independently selected from a group consisting of: H, halogen, alkyl, alkyl substituted with at least one halogen, aryl, aryl substituted with at least one halogen, —NRy1Ry2, —ORy1, —Ry1C(O)Ry3, —C(O)Ry1, —C(O)ORy2, —C(O)ORy2Ry3, —NRy1C(O)Ry2, —NRy1C(O)NRy2Ry3, —NRy1C(O)ORy2Ry3, —NRy1C(O)Ry2ORy3, C(O)NRy1(Ry2Ry3), —C(O)NRy1(Ry2ORy1), —ORy2Ry3, and —ORy2ORy3, wherein each of Ry1 and Ry2 is independently selected from a group consisting of H, oxygen, alkyl, and aryl, and Ry3 is aryl optionally substituted with at least one halogen; Z is —NRz1Rz2, —NRz1Rz3, —ORz1, —ORz1Rz3, —C(O)Rz1Rz3, —C(O)ORz1Rz3, —NRz1C(O)Rz2Rz3, —NRz1C(O)ORz2Rz3, —C(O)NRz1Rz3, or ORz2ORz3, wherein each of Rz1 and Rz2 is independently sel

Abstract: The present disclosure provides a benzene fused heterocyclic compound of Formula (I): wherein (A) is a single or double bond; n is 0 or 1; X is —CH2—, O, NR1, or S; A is —C(Ra1)(Ra2)(Ra3) or —N(Ra1)(Ra2), wherein Ra1, Ra2 and Ra3 are independently selected from a group consisting of: H, alkyl, cycloalkyl, heterocyclic alkyl, aryl, heteroaryl, C1-C3 hydrocarbon, —RaaORbb, —C(O)ORaaRbb, —C(O)RaaRbb, —C(O)NRaaRbb, —SO2 RaaRbb and —SO2 NRaaRbb which are optionally substituted by at least one substituent independently selected from a group consisting of: alkyl, cycloalkyl, heterocyclic alkyl, aryl, —Ybb, —ArbbYbb, —ORcc, and —OArbbYbb, wherein Raa, Rbb and Rcc independently are nil, H, halogen, alkyl, or aryl, Ybb is CN or halogen, and Araa and Arbb independently are aryl or heteroaryl; R1 is H or alkyl; R2 is alkyl, cycloalkyl, heterocylic alkyl, aryl, heteroaryl, C1-C6 hydrocarbon optionally substituted by at least one substituent independently selected from a group consisting of: —R2aOR2b, —R2aC(O)OR2bR2c, —R2a

Abstract: The present invention relates to morphinans selected from nalmefene and naltrexone and their related derivatives of formula (I), and pharmaceutical formulations thereof, for use in the prevention and treatment of a liver disease selected from the group consisting of NASH (non-alcoholic steatohepatitis), NAFLD (non-alcoholic fatty liver disease) and ASH (alcoholic steatohepatitis).

Abstract: The present invention relates to new medical uses of morphinans such as nalmefene and naltrexone and their related derivatives, pharmaceutical formulations thereof, and use thereof for prevention and treatment of NASH, NAFLD, and/or ASH.

Abstract: The present invention relates to new medical uses of morphinans such as nalmefene and naltrexone and their related derivatives, pharmaceutical formulations thereof, and use thereof for prevention and treatment of NASH, NAFLD, and/or ASH.

Abstract: The present invention relates to opioid and opioid-like compounds, and pharmaceutical formulations thereof, and use thereof for prevention and treatment of disorders such as septic shock and organ damage.

Abstract: The present invention relates to new medical uses of morphinans such as naltrexone, nalmefene and their related derivatives. The present invention relates to Toll-like receptor 4 (TLR4) antagonist compounds, and pharmaceutical formulations thereof, and use thereof for prevention and treatment of autoimmune liver diseases including but not limited to autoimmune hepatitis.